CAPLYTA is approved for a broad range of adults with bipolar depression1
The first and only treatment for depressive episodes associated with bipolar I and bipolar II depression in adults as monotherapy and adjunctive therapy with lithium or valproate1
Clinical studies evaluating adults with a depressive episode associated with bipolar disorder (bipolar depression)1,2
|MonotherapyBipolar IBipolar II||Adjunctive |
(with lithium or valproate)Bipolar IBipolar II
|MonotherapyBP IBP II||Adjunctive*BP IBP II|
|Quetiapine/ Quetiapine XR||yesyes|
*With lithium or valproate.
There are no head-to-head clinical studies comparing the safety and efficacy of these products. This chart is descriptive of the FDA-approved indications in adults with bipolar depression and does not represent all approved indications for each product.
References: 1. CAPLYTA prescribing information, 2022.
2. Data on File. 2021.